ProJenX Revenue and Competitors
Estimated Revenue & Valuation
- ProJenX's estimated annual revenue is currently $1.4M per year.
- ProJenX's estimated revenue per employee is $155,000
Employee Data
- ProJenX has 9 Employees.
- ProJenX grew their employee count by 50% last year.
ProJenX's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President and CEO | Reveal Email/Phone |
2 | Chief Operating Officer | Reveal Email/Phone |
ProJenX Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | 0% | N/A | N/A |
#2 | $3.7M | 24 | 41% | $44M | N/A |
#3 | $6.2M | 40 | -7% | N/A | N/A |
#4 | $42M | 271 | -1% | N/A | N/A |
#5 | $12.7M | 82 | 0% | $10M | N/A |
#6 | $2.5M | 16 | 0% | N/A | N/A |
#7 | $7.5M | 45 | 0% | $51.6M | N/A |
#8 | $0.2M | 1 | -50% | N/A | N/A |
#9 | $4.3M | 26 | -16% | $3.3M | N/A |
#10 | $3.7M | 24 | 4% | N/A | N/A |
What Is ProJenX?
ProJenX is a clinical-stage biotechnology company with novel, targeted, brain-penetrant therapies to address neurodegenerative diseases, with an initial focus on ALS. ProJenX was created out of a long-term research collaboration between Project ALS and Columbia University to rapidly develop and commercialize its lead therapy candidate, prosetin, for people with ALS. At the heart of ProJenX’s discoveries is an innovative, patient-specific, cell-based discovery platform that can be leveraged for the creation of additional transformative neuroscience medicines.
keywords:N/A
N/A
Total Funding
9
Number of Employees
$1.4M
Revenue (est)
50%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.2M | 9 | 0% | $14.4M |
#2 | $0.7M | 9 | 0% | N/A |
#3 | $0.2M | 9 | -25% | $67M |
#4 | $0.1M | 9 | 0% | $49M |
#5 | $0.5M | 9 | 0% | N/A |